denbufylline and adenine

denbufylline has been researched along with adenine in 2 studies

*Adenine: A purine base and a fundamental unit of ADENINE NUCLEOTIDES. [MeSH]

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bourguignon, JJ; Lugnier, C; Muller, CD; Pinna, G; Raboisson, P; Reimund, JM	1
Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I	1

Other Studies

2 other study(ies) available for denbufylline and adenine

Article	Year
Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties. Biochemical and biophysical research communications, 2001, Oct-26, Volume: 288, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Benzamides; Cell Survival; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Drug Interactions; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Lipopolysaccharides; Pentoxifylline; Phosphodiesterase Inhibitors; Pyridines; Tumor Necrosis Factor-alpha; Xanthines	2001
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PloS one, 2012, Volume: 7, Issue:1 Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Female; Humans; Isoenzymes; Kidney; Lipopolysaccharides; Lupus Erythematosus, Systemic; Mice; Mice, Inbred CBA; Mice, Inbred MRL lpr; Pentoxifylline; Phosphodiesterase 4 Inhibitors; Proteinuria; Survival Rate; Tumor Necrosis Factor-alpha; Xanthines	2012

Article

Year

Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.

Biochemical and biophysical research communications, 2001, Oct-26, Volume: 288, Issue:2

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Benzamides; Cell Survival; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Drug Interactions; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Lipopolysaccharides; Pentoxifylline; Phosphodiesterase Inhibitors; Pyridines; Tumor Necrosis Factor-alpha; Xanthines

2001

Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.

PloS one, 2012, Volume: 7, Issue:1

Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Female; Humans; Isoenzymes; Kidney; Lipopolysaccharides; Lupus Erythematosus, Systemic; Mice; Mice, Inbred CBA; Mice, Inbred MRL lpr; Pentoxifylline; Phosphodiesterase 4 Inhibitors; Proteinuria; Survival Rate; Tumor Necrosis Factor-alpha; Xanthines

2012